← Back to Clinical Trials
Recruiting NCT07081412

NCT07081412 Home-Based Transcutaneous Remotely Monitored Posterior Tibial Neuromodulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07081412
Status Recruiting
Phase
Sponsor Ege University
Condition Overactive Bladder Syndrome
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-06-24
Primary Completion 2026-12-31

Trial Parameters

Condition Overactive Bladder Syndrome
Sponsor Ege University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2025-06-24
Completion 2026-12-31
Interventions
Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a test device at 12 week and 12 monthEfficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a placebo device at 12 week

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To record the T-PTNS device (SmartUric) treatment performed by the patient at home via a mobile application in a remotely monitorable, secure and interactive manner with registration notes and a sham control group.

Eligibility Criteria

Inclusion Criteria: 1. Patients who are ≥18 years old and female patients diagnosed with OAB\* in Urology or Urogynecology outpatient clinics and who meet the inclusion criteria 2. Being able to continue their T-PTNS\*\* treatment at home with the mobile application and accepting this, 3. Having a smartphone compatible with the application for T-PTNS and being able to use the application 4. Agreeing to be followed up for one year after treatment, 5. Having stopped all antimuscarinics for at least two weeks, 6. Being able to stand and use the toilet independently without difficulty, 7. Volunteers who are willing to participate, have been informed about the study and have given signed informed consent, stating that they can comply with the requirements and restrictions listed in the informed consent form (ICP) and this protocol. Exclusion Criteria: 1. Patients under the age of 18 2. Patients who are pregnant according to the results of a pregnancy test with urine or blood test, or who ar

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology